CILIATECH is developing a groundbreaking concept called CID (Cilio-scleral Interpositioning Device): a new class of implant to address the increasing need to treat glaucoma durably and with zero adverse effects. INTERCIL® Uveal Spacer is the first implant in the industry to reduce IOP without penetrating the anterior chamber or creating subconjunctival filtration, for open and narrow angle patients. Clinical trials show IOP is reduced by 33% at 36 months (68% patients drop free, no reoperation needed) and without ECL risk.
